Skip to main content
OpenAI employee fired for insider trading on Sora, GPT-5, ChatGPT Browser, and Altman's status.

Editorial illustration for OpenAI fires employee for trades on Sora, GPT‑5, ChatGPT Browser, Altman status

OpenAI Fires Employee Over Insider Trading Scandal

OpenAI fires employee for trades on Sora, GPT‑5, ChatGPT Browser, Altman status

Updated: 3 min read

Sam Altman’s abrupt ouster in November 2023 lasted only days. But for one anonymous trader, it was a golden window. A fresh wallet placed a $16,000 bet on his return, and won.

That single trade now looks like a canary in a coal mine. In the 40 hours before OpenAI launched its browser, 13 wallets with zero trading history materialized from nowhere. Their collective bet: $309,486, all on the correct outcome.

These aren’t coincidences. They are the fingerprints of insider trading. And OpenAI has responded by firing an employee.

The question is: how deep does the leak go?

Suspicious trades hinged on the release dates of products like Sora, GPT-5, and the ChatGPT Browser, as well as CEO Sam Altman's employment status. In November 2023, two days after Altman was dramatically ousted from the company, a new wallet placed a significant bet that he would return, netting over $16,000 in profits. The behavior fits into patterns typical of insider trades. In the 40 hours before OpenAI launched its browser, 13 brand-new wallets with zero trading history appeared on the site for the first time to collectively bet $309,486 on the right outcome," says Unusual Whales CEO Matt Saincome.

This is the moment where the line between speculation and sabotage blurs into something far more dangerous. OpenAI’s decision to fire an employee for gaming prediction markets isn’t just about punishing one bad actor. It’s a stark admission that the company’s own internal clockwork, its launch dates, its leadership jolts, its product roadmaps, has become a trading floor for those who can read the code.

Matt Saincome of Unusual Whales laid out the cold arithmetic: brand-new wallets, zero history, suddenly betting hundreds of thousands on the right outcome with surgical precision. That’s not luck. That’s a leak.

The signal is unmistakable. Prediction markets thrive on asymmetry, and OpenAI just proved it cannot afford to let its own people exploit the gap between what they know and what the world guesses. Firing one employee is a move that feels decisive, but it also opens a deeper question: how many others knew the exact shape of the next product before the rest of us saw its shadow?

The company has now drawn a bright red circle around a lesson that every insider should fear. The market may be fast, but the severance is faster.

Common Questions Answered

What specific actions did OpenAI take against an employee involved in prediction market trades?

OpenAI dismissed a staff member after an internal investigation revealed they were trading on confidential information about upcoming product releases. Fidji Simo, the CEO of Applications, confirmed the termination in an internal memo, stating the employee used confidential OpenAI information in external prediction markets like Polymarket.

What were the key products and events involved in the suspicious prediction market trades?

The suspicious trades centered on upcoming OpenAI products including Sora, GPT-5, and the ChatGPT Browser, as well as speculation about CEO Sam Altman's employment status. One notable example was a significant bet placed two days after Altman's November 2023 ousting, which netted over $16,000 in profits when he was subsequently reinstated.

How did OpenAI respond to the potential insider trading of confidential information?

OpenAI took a strict approach by terminating the employee who allegedly exploited confidential product timelines and leadership information for external prediction market trades. The company's action demonstrates its commitment to enforcing an insider-trading policy and protecting sensitive corporate information from unauthorized speculation.

LIVE03:21OpenAI's Miles Wang in Talks for USD 2B AI Drug Discovery Startup